These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29423068)

  • 1. FoxM1 and β-catenin predicts aggressiveness in Middle Eastern ovarian cancer and their co-targeting impairs the growth of ovarian cancer cells.
    Pratheeshkumar P; Divya SP; Parvathareddy SK; Alhoshani NM; Al-Badawi IA; Tulbah A; Al-Dayel F; Siraj AK; Al-Kuraya KS
    Oncotarget; 2018 Jan; 9(3):3590-3604. PubMed ID: 29423068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.
    Chan DW; Hui WW; Cai PC; Liu MX; Yung MM; Mak CS; Leung TH; Chan KK; Ngan HY
    PLoS One; 2012; 7(12):e52578. PubMed ID: 23285101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer.
    Siraj AK; Pratheeshkumar P; Parvathareddy SK; Qadri Z; Thangavel S; Ahmed S; Al-Dayel F; Tulbah A; Ajarim D; Al-Kuraya KS
    Oncotarget; 2018 Apr; 9(25):17466-17482. PubMed ID: 29707121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
    Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
    Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
    Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
    Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
    Cianfrocca R; Tocci P; Spinella F; Di Castro V; Bagnato A; Rosanò L
    Life Sci; 2012 Oct; 91(13-14):550-6. PubMed ID: 22480520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling.
    Quan M; Cui J; Xia T; Jia Z; Xie D; Wei D; Huang S; Huang Q; Zheng S; Xie K
    Cancer Res; 2015 Nov; 75(22):4778-4789. PubMed ID: 26483206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer.
    Chen Y; Ruben EA; Rajadas J; Teng NNH
    Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
    Wang T; Liu Z; Shi F; Wang J
    Mol Cell Biochem; 2016 Feb; 413(1-2):179-87. PubMed ID: 26820938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing PPA1 inhibits human epithelial ovarian cancer metastasis by suppressing the Wnt/β-catenin signaling pathway.
    Niu H; Zhou W; Xu Y; Yin Z; Shen W; Ye Z; Liu Y; Chen Y; Yang S; Xiang R; Wang L; Qu P
    Oncotarget; 2017 Sep; 8(44):76266-76278. PubMed ID: 29100310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma.
    Ito T; Kohashi K; Yamada Y; Maekawa A; Kuda M; Furue M; Oda Y
    Histopathology; 2016 Jul; 69(1):63-71. PubMed ID: 26619071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy.
    Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N
    Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
    Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
    BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of
    Meng F; Ding J; Xu W; Luo C; Chen X; Zhang R; Sui L; Hu Y; Liu S; Shi G; He Y; Ning X; Ma R; Huang N
    Transl Cancer Res; 2022 Feb; 11(2):414-425. PubMed ID: 35281418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocyte-derived CCDC3 promotes tumorigenesis in epithelial ovarian cancer through the Wnt/ß-catenin signalling pathway.
    Wang F; Jin F; Peng S; Li C; Wang L; Wang S
    Biochem Biophys Rep; 2023 Sep; 35():101507. PubMed ID: 37601453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.
    Wang FQ; Barfield E; Dutta S; Pua T; Fishman DA
    Gynecol Oncol; 2009 Dec; 115(3):414-23. PubMed ID: 19765808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rab11a sustains GSK3β/Wnt/β-catenin signaling to enhance cancer progression in pancreatic cancer.
    Yu L; Li X; Li H; Chen H; Liu H
    Tumour Biol; 2016 Oct; 37(10):13821-13829. PubMed ID: 27481517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-catenin and Kras/Foxm1 signaling pathway are critical to restrict Sox9 in basal cells during pulmonary branching morphogenesis.
    Ustiyan V; Zhang Y; Perl AK; Whitsett JA; Kalin TV; Kalinichenko VV
    Dev Dyn; 2016 May; 245(5):590-604. PubMed ID: 26869074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo.
    Brückner L; Reinshagen A; Hoang NA; Höhn AK; Lordick F; Bechmann I; Aktas B; Nel I; Kallendrusch S
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.